

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## **Decision Cover Letter**

### **Decision of the licensing authority to:**

agree a paediatric investigation plan and grant a deferral and grant a waiver

MHRA-102050-PIP01-25

### **Scope of the Application**

#### **Active Substance(s)**

Aficamten

#### **Condition(s)**

Treatment of hypertrophic cardiomyopathy

#### **Pharmaceutical Form(s)**

Tablet

#### **Route(s) of Administration**

ORAL USE

#### **Name / Corporate name of the PIP applicant**

CYTOKINETICS (IRELAND) LIMITED

#### **Basis for the Decision**

Pursuant to the Human Medicines Regulations 2012, CYTOKINETICS (IRELAND) LIMITED submitted to the licensing authority on 18/09/2025 15:06 BST an application for a Paediatric Investigation Plan

The procedure started on 04/11/2025 10:54 GMT

1. The licensing authority, having assessed the application in accordance with the Human Medicines Regulations 2012, decides, as set out in the appended summary report:

to agree a paediatric investigation plan and grant a deferral and grant a waiver

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This decision is forwarded to the applicant, together with its annex and appendix.

**MHRA**  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU  
United Kingdom

[gov.uk/mhra](http://gov.uk/mhra)

## Final Decision Letter

MHRA-102050-PIP01-25

Of 12/01/2026 09:33 GMT

On the adopted decision for Aficamten (MHRA-102050-PIP01-25) in accordance with the Human Medicines Regulations 2012.

The licensing authority, in accordance with the Human Medicines Regulations 2012, has adopted this decision:

Agreement on a paediatric investigation plan

This decision applies to a Paediatric Investigation Plan for Aficamten, Tablet , ORAL USE .

This decision is addressed to CYTOKINETICS (IRELAND) LIMITED , 2ND FLOOR PALMERSTON HOUSE, DENZILLE LANE, DUBLIN 2, D02 WD37, IRELAND, Dublin, IRELAND, D02 WD37

## ANNEX I

### 1. Waiver

#### 1.1 Condition:

Treatment of hypertrophic cardiomyopathy The waiver applies / applied to: Paediatric Subset(s): The paediatric population from birth to less than 6 years of age Pharmaceutical form(s): Tablet Route(s) of administration: ORAL USE Reason for granting waiver: on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible

### 2. Paediatric Investigation Plan:

#### 2.1 Condition(s):

Treatment of hypertrophic cardiomyopathy

#### 2.2 Indication(s) targeted by the PIP:

Treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM)

### 2.3 Subset(s) of the paediatric population concerned by the paediatric development:

The paediatric population from 6 years to less than 18 years of age

### 2.4 Pharmaceutical Form(s):

Tablet

### 2.5 Studies:

Study Type	Number of Studies	Study Description
Quality Measures	1	Study 1 (PED-FORMDEV-1) Development of age-appropriate dosage strength(s).
Non-Clinical Studies	2	Study 2 (JUV-TOX-1) Dose range-finding juvenile toxicity study. Study 3 (JUV-TOX-2) Definitive juvenile toxicity study.
Clinical Studies	1	Study 4 Randomised, double-blind, placebo-controlled, 2-arm, parallel group, 2-period study to evaluate the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of aficamten compared to placebo (Period 1) followed by long-term, open-label assessment of safety and PD (Period 2) in children from 6 years to less than 18 years of age with symptomatic sarcomeric obstructive hypertrophic cardiomyopathy (oHCM).
Extrapolation, Modeling & Simulation Studies	2	Study 5 Modelling and simulation study to support dose finding of the product in children from 6 years to less than 18 years of age with oHCM, based on data from adults and adolescents. Study 6 Modelling and simulation study to adjust the dose of the product in children from 6 years to less than 18 years of age with oHCM, on incorporation of PK/PD data from Study 4.
Other Studies	0	Not applicable.
Other Measures	0	Not applicable.

### 3. Follow-up, completion and deferral of a PIP:

<b>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</b>	No
<b>Date of completion of the paediatric investigation plan:</b>	30/04/2030
<b>Deferral of one or more studies contained in the paediatric investigation plan:</b>	Yes